Effects of the metal type and the roughness of the die wall on the expended work for tablet ejection

Pharmaceutical Development and Technology

Volumn 5, Issue 1, 2000, Pages 19-26

  Otz, Markus ^a   Thoma, Hubert ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cemented carbide; Die wall composition; Die wall properties; DIN 145 Cr 6; DIN 4768; Hard alloy; Hard metal; ISO 4287; ISO K40; Roughness of die wall; Tablet ejection force; Tablet ejection work; Tool steel

Indexed keywords

MAGNESIUM STEARATE; METAL; SILICON DIOXIDE;

ARTICLE; DRUG FORMULATION; DRUG MANUFACTURE; PHARMACEUTICAL ENGINEERING; PHYSICAL PARAMETERS; PRIORITY JOURNAL; TABLET; TABLET MANUFACTURE;

CHEMISTRY, PHARMACEUTICAL; COMPRESSIVE STRENGTH; LUBRICATION; METALS; SILICON DIOXIDE; STEARIC ACIDS; TABLETS; TIME FACTORS;

EID: 0033978576     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-100100515     Document Type: Article

References (7)

1. International Pharmaceutical Abstracts, American Society of Health-System Pharmacists, Inc., Bethesda, MD, 1970-1998; WinSPIRS™, Version 2.1 B2.2, SilverPlatter International, NV, 1990-1998.
2. International Pharmaceutical Abstracts, American Society of Health-System Pharmacists, Inc., Bethesda, MD, 1970-1998; WinSPIRS™, Version 2.1 B2.2, SilverPlatter International, NV, 1990-1998.
3. Tungsten (lapis ponderosus or heavy stone), International Tungsten Industry Association, 1997 (http://www.itia. org.uk/tungtext1.htm).
4. P. E. Wray, The physics of tablet compaction revisited, Drag Dev. Ind. Pharm., 18(6, 7), 627-658 (1992).
5. Tableting Specification Manual, 4th ed., American Pharmaceutical Association, Washington, DC, 1995.
6. SAS Institute Inc., SAS/LAB® Software, User's Guide, Version 6, 1st ed., SAS Institute Inc., Cary, NC, 1992.
7. SUPAC-IR: Immediate-release solid oral dosage forms: scale-up and post-approval changes: Chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Washington, DC, November 1995.